On the heels of another successful Desmoid Tumor Awareness Month, we are thrilled to formally announce The Desmoid Tumor Research Foundation Grant Awards for 2022!
The proposals from these institutions offer the potential for significant advancements in desmoid tumor research and align with the research priorities set by our Scientific Advisory Board. For more information, visit DTRF-Awarded Grants.
Funding for these critical projects would not be possible without the continued support of our community and donors – YOU! We would like to extend an additional special thank you to the families who have helped fund some of these important projects.
The awards below are contingent upon a mutually agreed upon grant agreement.
To mark this exciting announcement, please consider sharing this news and/or making a donation today.
- Sameer Rastogi, MD, Aiims- All India Institute of Medical Science,New Delhi, “To see the early effect of sorafenib on cognition, cardiovascular and reproductive functions in patients with fibromatosis.”
- Cristabelle De Souza, PhD, Stanford University, “Activation of c-JUN modulates the transcriptional activity of CD63 serving as a novel target for the treatment of Desmoid Type Fibromatosis.” Jointly funded by the DTRF and Desmoid Tumour Foundation of Canada (DFC)
- Joanna Przybyl, PhD, Research Institute – Centre universitaire de santé McGill – McGill University Health Centre, “Targeting hexosamine biosynthesis pathway for the treatment of desmoid tumors.” Jointly funded by the DTRF and Desmoid Tumour Foundation of Canada (DFC)
- Jonathan Noujaim, MD, #CanSaRCC, “Tyrosine Kinase Inhibitors in Desmoid-type Fibromatosis- A Canadian Multicenter Retrospective CanSaRCC Study.” Jointly funded by the DTRF and Desmoid Tumour Foundation of Canada (DFC)
- Kris Vleminckx, PhD, Universiteit Gent, “Investigating EZH2 as a druggable mediator of immune cell exclusion in desmoid tumors.” Year 2 of 2. Jointly funded by the DTRF and Desmoid Tumour Foundation of Canada (DFC)
- Gerlinde Wernig, MD, Stanford Medicine, Department of Pathology, “Studying CD47 blockade as an immunotherapy for desmoid-type fibromatosis.” Year 2 of 2.
Thank you for your support in our mission to find a cure for desmoid tumors!
